Terms: = Head and neck cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Staging
11 results:
1. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
[TBL] [Abstract] [Full Text] [Related]
2. Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake Correlates with kras and EMT Gene Signatures in Operable Esophageal Adenocarcinoma.
Heiden BT; Patel N; Nancarrow DJ; Hermann M; Brown RKJ; Orringer MB; Lin J; Chang AC; Carrott PW; Lynch WR; Zhao L; Beer DG; Reddy RM
J Surg Res; 2018 Dec; 232():621-628. PubMed ID: 30463782
[TBL] [Abstract] [Full Text] [Related]
3. Mutually exclusive recurrent kras and MAP2K1 mutations in Rosai-Dorfman disease.
Garces S; Medeiros LJ; Patel KP; Li S; Pina-Oviedo S; Li J; Garces JC; Khoury JD; Yin CC
Mod Pathol; 2017 Oct; 30(10):1367-1377. PubMed ID: 28664935
[TBL] [Abstract] [Full Text] [Related]
4. Characterization and effects of miR-21 expression in esophageal cancer.
Wen SW; Zhang YF; Li Y; Liu ZX; Lv HL; Li ZH; Xu YZ; Zhu YG; Tian ZQ
Genet Mol Res; 2015 Aug; 14(3):8810-8. PubMed ID: 26345812
[TBL] [Abstract] [Full Text] [Related]
5. An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung.
Zenali MJ; Weissferdt A; Solis LM; Ali S; Tang X; Mehran RJ; Wistuba II; Moran CA; Kalhor N
Hum Pathol; 2015 Jun; 46(6):836-42. PubMed ID: 25776025
[TBL] [Abstract] [Full Text] [Related]
6. Human papillomavirus and gene mutations in head and neck squamous carcinomas.
Friedland P; Thomas A; Naran A; Amanuel B; Grieu-Iacopetta F; Carrello A; Harnett G; Meyer C; Phillips M
ANZ J Surg; 2012 May; 82(5):362-6. PubMed ID: 22507644
[TBL] [Abstract] [Full Text] [Related]
7. Comparison of oncogene mutation detection and telomerase activity for the molecular staging of non-small cell lung cancer.
Ahrendt SA; Yang SC; Wu L; Westra WH; Jen J; Califano JA; Sidransky D
Clin Cancer Res; 1997 Jul; 3(7):1207-14. PubMed ID: 9815801
[TBL] [Abstract] [Full Text] [Related]
8. [Incidence of point mutations in ki-ras codon 12 and 13 in squamous epithelial carcinomas of the head-neck region].
Rathcke IO; Gottschlich S; Görögh T; Lippert BM; Werner JA
Laryngorhinootologie; 1996 Aug; 75(8):465-70. PubMed ID: 8962608
[TBL] [Abstract] [Full Text] [Related]
9. Picture archiving and communications systems in radiation oncology (PACSRO): tools for a physician-based digital image review system.
McGee KP; Das IJ; Fein DA; Martin EE; Schultheiss TE; Hanks GE
Radiother Oncol; 1995 Jan; 34(1):54-62. PubMed ID: 7792399
[TBL] [Abstract] [Full Text] [Related]
10. ras mutations and expression in head and neck squamous cell carcinomas.
Yarbrough WG; Shores C; Witsell DL; Weissler MC; Fidler ME; Gilmer TM
Laryngoscope; 1994 Nov; 104(11 Pt 1):1337-47. PubMed ID: 7968162
[TBL] [Abstract] [Full Text] [Related]
11. Clinical relevance of oncogene expression in head and neck tumours.
Field JK; Lamothe A; Spandidos DA
Anticancer Res; 1986; 6(4):595-600. PubMed ID: 3019219
[TBL] [Abstract] [Full Text] [Related]
